CVD and Renal Disease in T2DM: Individualizing Therapeutic Options to Reduce Comorbid Risk
Registration

By clicking the continue button above, I certify that I have read the CME Statements below.

A Series of CME-/AAFP-certified Activities

FACULTY
 Prakash Deedwania, MD, FACC, FAHA, FACP, FHFSA, FESC
 Professor of Medicine
 UCSF School of Medicine
 San Francisco, CA 

 

 

 

 Ellen H. Miller, MD
 Professor of Science Education, Medicine, and Obstetrics and Gynecology
 Donald and Barbara Zucker School of Medicine at Hofstra/Northwell
 Senior Medical Director
 North Shore - LIJ CareConnect
 East Hills, NY

 

 

PROGRAM OVERVIEW
Type 2 diabetes mellitus (T2DM) continues to pose a major public-health problem. This disease can be further complicated by the presence of comorbidities, specifically cardiovascular disease (CVD) and renal complications. CVD not only remains the leading cause of death in T2DM patients, the presence of cardiovascular complications reduces patient quality of life. Chronic kidney disease, often underdiagnosed until later stages of disease, also increases the risk of CVD in patients with T2DM. Reduction of cardiovascular risk through lifestyle intervention and pharmacologic therapy in patients with T2DM is critical.

AGENDA
Welcome, Introductions, and Pre-Survey
Individualizing Antihyperglycemic Therapy: Guideline-based Recommendations
Managing Cardiovascular and Renal Comorbidities in T2DM
Q&A Session and Concluding Remarks

TARGET AUDIENCE
This activity is intended for family physicians, including primary care physicians and internal medicine specialists, who manage patients with T2DM.

EDUCATIONAL OBJECTIVES

At the conclusion of this activity, participants should be able to:

  • Utilize evidence-based recommendations to individualize pharmacologic treatment options for patients with T2DM
  • Recognize the cardiovascular and renal benefits associated with glucose lowering therapies in order to optimally manage patients with T2DM and associated comorbidities

ACCREDITATION STATEMENT

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Boston University School of Medicine and Rockpointe. Boston University School of Medicine is accredited by the ACCME to provide continuing medical education for physicians.

DESIGNATION STATEMENT

Boston University School of Medicine designates this live activity for a maximum of 1.00 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
For information about the accreditation of this program, please email: cme@bu.edu.

AMERICAN ACADEMY OF FAMILY PHYSICIANS (AAFP)

This Live activity, CVD AND RENAL DISEASE IN T2DM: Individualizing Therapeutic Options to Reduce Comorbid Risk, from 11/8/2018 - 3/28/2019, has been reviewed and is acceptable for up to 1.00 Prescribed credits by the American Academy of Family Physicians. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

DISCLOSURE STATEMENT
This educational activity has been produced in adherence with the policies and guidelines, including the Standards for Commercial Support, set forth to providers by the Accreditation Council for Continuing Medical Education (ACCME) and all other professional organizations, as applicable, stating those activities where continuing education credits are awarded must be balanced, independent, objective, and scientifically rigorous.

Boston University School of Medicine asks all individuals, and their spouses/partners, involved in the development and presentation of Continuing Medical Education (CME) activities to disclose all relevant financial relationships with commercial interests. This information is disclosed to CME activity participants prior to the start of the educational activity. Boston University School of Medicine has procedures to resolve all conflicts of interest. In addition, faculty members are asked to disclose when any unapproved use of pharmaceuticals and devices is being discussed.

BUSM DISCLAIMER
THESE MATERIALS AND ALL OTHER MATERIALS PROVIDED IN CONJUNCTION WITH CONTINUING MEDICAL EDUCATION ACTIVITIES ARE INTENDED SOLELY FOR PURPOSES OF SUPPLEMENTING CONTINUING MEDICAL EDUCATION PROGRAMS FOR QUALIFIED HEALTH CARE PROFESSIONALS. ANYONE USING THE MATERIALS ASSUMES FULL RESPONSIBILITY AND ALL RISK FOR THEIR APPROPRIATE USE. TRUSTEES OF BOSTON UNIVERSITY MAKES NO WARRANTIES OR REPRESENTATIONS WHATSOEVER REGARDING THE ACCURACY, COMPLETENESS, CURRENTNESS, NONINFRINGEMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE OF THE MATERIALS. IN NO EVENT WILL TRUSTEES OF BOSTON UNIVERSITY BE LIABLE TO ANYONE FOR ANY DECISION MADE OR ACTION TAKEN IN RELIANCE ON THE MATERIALS. IN NO EVENT SHOULD THE INFORMATION IN THE MATERIALS BE USED AS A SUBSTITUTE FOR PROFESSIONAL CARE.

METHOD OF PARTICIPATION
To complete the activity and receive credit, the participant must attend the program and complete the evaluation form. A CME certificate will be presented after submission of a completed evaluation form.

There are no fees associated with this program.

SPECIAL SERVICES
Event staff will be glad to assist you with any specials needs (e.g. physical, dietary, etc.).  Please email specialservices@rockpointe-pcme.com at least 5 days prior to the program.

Jointly provided by Boston University School of Medicine and Rockpointe

      

This activity is supported by an independent educational grant from AstraZeneca, Boehringer Ingelheim ​Pharmaceuticals, Inc., Lilly USA, and Novo Nordisk Inc.